Wang Y, Jia W, Cynader M
Department of Ophthalmology, University of British Columbia, Vancouver, Canada.
Neuroreport. 1997 Oct 20;8(15):3323-6. doi: 10.1097/00001756-199710200-00026.
The neuroprotective effects of the NMDA receptor blocker APV were compared with those of bcl-2 in a glutamate-induced excitotoxic cell death model in cultured rat cortical neurons. Exposure to 100 microM glutamate for 5 h caused approximately 95% of the cultured neurons to die in 24 h. The NMDA-selective antagonist D-(-)-2-amino-5-phosphonopentanoate (APV) protected the neurons effectively when applied prior to or soon after glutamate treatment. However, infection with a viral vector expressing the proto-oncogene bcl-2 strongly protected neurons even if applied as late as 8 h following the glutamate insult. These data provides evidence that APV blocks an early stage of the death cascade in response to elevations of glutamate. By contrast bcl-2 appears to act at a fairly late stage in the cell death process and these results suggest a possible clinical role in treatment of ischemic brain disorders.
在培养的大鼠皮质神经元谷氨酸诱导的兴奋性毒性细胞死亡模型中,将N-甲基-D-天冬氨酸(NMDA)受体阻滞剂APV的神经保护作用与bcl-2的神经保护作用进行了比较。暴露于100微摩尔谷氨酸5小时导致约95%的培养神经元在24小时内死亡。NMDA选择性拮抗剂D-(-)-2-氨基-5-磷酸戊酸(APV)在谷氨酸处理之前或之后不久应用时能有效保护神经元。然而,即使在谷氨酸损伤后8小时才应用,用表达原癌基因bcl-2的病毒载体感染也能强烈保护神经元。这些数据证明APV阻断了谷氨酸升高引起的死亡级联反应的早期阶段。相比之下,bcl-2似乎在细胞死亡过程的相当后期起作用,这些结果提示其在缺血性脑疾病治疗中可能具有临床作用。